Literature DB >> 1737238

Vertebral osteoporosis in rheumatoid arthritis patients: effect of low dose prednisone therapy.

R F Laan1, P L van Riel, L J van Erning, J A Lemmens, S H Ruijs, L B van de Putte.   

Abstract

The effect of low dose prednisone therapy on spinal bone mass is controversial. We measured lumbar trabecular and cortical bone mineral density (BMD) in 74 rheumatoid arthritis (RA) patients by dual energy quantitative computerized tomography in a cross-sectional study. The presence of vertebral deformities was evaluated on a lateral spine radiograph. Patients who had never been treated with corticosteroids (n = 44) were compared with patients on long-term low dose (less than or equal to 10 mg/day) prednisone therapy (n = 30). After correction for confounding variables the lumbar BMD was highly significantly influenced by prednisone therapy in postmenopausal patients (estimated influence -31.2% on trabecular BMD and -37.2% on cortical BMD). Vertebral deformities were also significantly more frequent in prednisone treated postmenopausal patients. No negative effect of prednisone treatment could be demonstrated in male patients. In contradiction to previous reports we conclude that long-term prednisone therapy may be associated with development of spinal osteoporosis in postmenopausal RA patients, even when low doses are used.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1737238     DOI: 10.1093/rheumatology/31.2.91

Source DB:  PubMed          Journal:  Br J Rheumatol        ISSN: 0263-7103


  25 in total

Review 1.  Bone mass in patients with rheumatoid arthritis.

Authors:  R F Laan; P L van Riel; L B van de Putte
Journal:  Ann Rheum Dis       Date:  1992-06       Impact factor: 19.103

2.  Body composition and vertebral fracture risk in female patients treated with glucocorticoid.

Authors:  H Kaji; T Tobimatsu; J Naito; M-F Iu; M Yamauchi; T Sugimoto; K Chihara
Journal:  Osteoporos Int       Date:  2005-12-31       Impact factor: 4.507

3.  Inhibitory effect of bone resorption and inflammation with etidronate therapy in patients with rheumatoid arthritis for 3 years and in vitro assay in arthritis models.

Authors:  Kaname Yamamoto; Shinichi Yoshino; Goukei Shue; Masakazu Nagashima
Journal:  Rheumatol Int       Date:  2005-08-27       Impact factor: 2.631

4.  Steroid osteoporosis.

Authors:  T D Spector; P N Sambrook
Journal:  BMJ       Date:  1993-08-28

5.  Treatment of osteoporosis of rheumatoid arthritis.

Authors:  F P Cantatore; M Carrozzo
Journal:  Clin Rheumatol       Date:  1995-09       Impact factor: 2.980

6.  Height loss rate as a marker of osteoporosis in postmenopausal women with rheumatoid arthritis.

Authors:  M Sanila; A Kotaniemi; J Viikari; H Isomäki
Journal:  Clin Rheumatol       Date:  1994-06       Impact factor: 2.980

7.  Comparison of ultrasound and X-ray absorptiometry bone measurements in a case control study of female rheumatoid arthritis patients and randomly selected subjects in the population.

Authors:  G Haugeberg; R E Ørstavik; T Uhlig; J A Falch; J I Halse; T K Kvien
Journal:  Osteoporos Int       Date:  2003-04-16       Impact factor: 4.507

Review 8.  Prevention and treatment of glucocorticoid-induced osteoporosis with active vitamin D3 analogues: a review with meta-analysis of randomized controlled trials including organ transplantation studies.

Authors:  R N J de Nijs; J W G Jacobs; A Algra; W F Lems; J W J Bijlsma
Journal:  Osteoporos Int       Date:  2004-05-07       Impact factor: 4.507

9.  Bone mineral density in nonsteroid treated early rheumatoid arthritis.

Authors:  B D Shenstone; A Mahmoud; R Woodward; D Elvins; R Palmer; F Ring; A K Bhalla
Journal:  Ann Rheum Dis       Date:  1994-10       Impact factor: 19.103

10.  Oral glucocorticoid use is associated with an increased risk of fracture.

Authors:  Michael Steinbuch; Thomas E Youket; Stanley Cohen
Journal:  Osteoporos Int       Date:  2004-02-05       Impact factor: 4.507

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.